(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 133.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Cytokinetics's revenue in 2026 is $67,670,000.On average, 24 Wall Street analysts forecast CYTK's revenue for 2026 to be $21,231,656,397, with the lowest CYTK revenue forecast at $15,067,358,043, and the highest CYTK revenue forecast at $32,467,529,040. On average, 23 Wall Street analysts forecast CYTK's revenue for 2027 to be $60,084,531,025, with the lowest CYTK revenue forecast at $43,161,210,352, and the highest CYTK revenue forecast at $84,241,240,137.
In 2028, CYTK is forecast to generate $125,079,369,175 in revenue, with the lowest revenue forecast at $95,272,748,355 and the highest revenue forecast at $160,154,977,536.